OBJECTIVES: The goal of this study was to assess whether a platelet rebound exists and whether it can be attenuated by clopidogrel tapering. BACKGROUND: Clinical studies have reported a clustering of thrombotic events after stopping clopidogrel treatment. The hypothesis of a rebound phenomenon of platelets has been declared causative, but its existence has never been confirmed. Tapering of clopidogrel over a certain period of time before stopping the drug completely might provide a way to attenuate this supposed phenomenon. METHODS:Patients (n = 69) receivingclopidogrel treatment due to prior drug-eluting stent placement and planning to stop clopidogrel were recruited in a double-blind, randomized trial. Patients were randomized to either receive a pre-specified tapering regimen (tapering group; n = 35) for 4 weeks with complete discontinuation of clopidogrel thereafter or continue a daily clopidogrel intake for 4 more weeks with abrupt discontinuation afterwards (off group; n = 34). Platelet aggregation (PA) was assessed with light transmission aggregometry (LTA) and multiple electrode aggregometry (MEA) simultaneously at study inclusion and at weeks 2 to 8 after randomization. The primary end point was the highest value of adenosine diphosphate-induced PA measured with LTA in the weeks after complete cessation of clopidogrel in both groups. RESULTS: The highest values of adenosine diphosphate-induced PA after complete cessation of clopidogrel were similar between both groups (p = 0.21 with LTA, and p = 0.55 with MEA). CONCLUSIONS: Tapering of clopidogrel does not result in lower PA values after clopidogrel withdrawal. The course of PA values after clopidogrel cessation provides no evidence for the existence of a rebound phenomenon of platelets. Copyright 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
RCT Entities:
OBJECTIVES: The goal of this study was to assess whether a platelet rebound exists and whether it can be attenuated by clopidogrel tapering. BACKGROUND: Clinical studies have reported a clustering of thrombotic events after stopping clopidogrel treatment. The hypothesis of a rebound phenomenon of platelets has been declared causative, but its existence has never been confirmed. Tapering of clopidogrel over a certain period of time before stopping the drug completely might provide a way to attenuate this supposed phenomenon. METHODS:Patients (n = 69) receiving clopidogrel treatment due to prior drug-eluting stent placement and planning to stop clopidogrel were recruited in a double-blind, randomized trial. Patients were randomized to either receive a pre-specified tapering regimen (tapering group; n = 35) for 4 weeks with complete discontinuation of clopidogrel thereafter or continue a daily clopidogrel intake for 4 more weeks with abrupt discontinuation afterwards (off group; n = 34). Platelet aggregation (PA) was assessed with light transmission aggregometry (LTA) and multiple electrode aggregometry (MEA) simultaneously at study inclusion and at weeks 2 to 8 after randomization. The primary end point was the highest value of adenosine diphosphate-induced PA measured with LTA in the weeks after complete cessation of clopidogrel in both groups. RESULTS: The highest values of adenosine diphosphate-induced PA after complete cessation of clopidogrel were similar between both groups (p = 0.21 with LTA, and p = 0.55 with MEA). CONCLUSIONS: Tapering of clopidogrel does not result in lower PA values after clopidogrel withdrawal. The course of PA values after clopidogrel cessation provides no evidence for the existence of a rebound phenomenon of platelets. Copyright 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Authors: Samuel Pearce; Julian T Maingard; Hong Kuan Kok; Christen D Barras; Jeremy H Russell; Joshua A Hirsch; Ronil V Chandra; Ash Jhamb; Vincent Thijs; Mark Brooks; Hamed Asadi Journal: Clin Neuroradiol Date: 2021-03-01 Impact factor: 3.649
Authors: Renato D Lopes; Richard C Becker; L Kristin Newby; Eric D Peterson; Elaine M Hylek; Christopher B Granger; Mark Crowther; Tracy Wang; Antonio C Carvalho; Otavio Berwanger; Roberto R Giraldez; Gilson Soares Feitosa; Jorge Pinto Ribeiro; Eduardo Darze; Renato A K Kalil; Marianna Andrande; Fabio Villas Boas; Jadelson Andrade; Ana Thereza Rocha; Robert A Harrington; Antonio C Lopes; David A Garcia Journal: J Thromb Thrombolysis Date: 2012-07 Impact factor: 2.300
Authors: Idit Yedidya; Adi Netzer; Muthiah Vaduganathan; Alejandro Solodky; Ran Kornowski; Eli I Lev Journal: J Thromb Thrombolysis Date: 2012-01 Impact factor: 2.300
Authors: Constance C F M J Baaten; Leo F Veenstra; Rick Wetzels; Johanna P van Geffen; Frauke Swieringa; Susanne M de Witt; Yvonne M C Henskens; Harry Crijns; Sven Nylander; J J J van Giezen; Johan W M Heemskerk; Paola E J van der Meijden Journal: Haematologica Date: 2015-06-25 Impact factor: 9.941
Authors: Philipp Diehl; Christoph Halscheid; Christoph Olivier; Thomas Helbing; Christoph Bode; Martin Moser Journal: Clin Res Cardiol Date: 2011-04-09 Impact factor: 5.460
Authors: Joseph A Jakubowski; Jeffrey S Riesmeyer; Sandra L Close; Amy G Leishman; David Erlinge Journal: Cardiovasc Ther Date: 2011-02-17 Impact factor: 3.023